-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to "China Heart Vascular Disease Report 2017," China brain stroke disease burden remains high, even on the rise
Heart vascular stroke cardiogenic embolism is a leading cause of ischemic stroke, ischemic stroke cent of all proportion as high as 26%, and disability and mortality was significantly higher than non-embolic cerebrovascular events
Arrhythmia is characterized by a high fatality rate and a high disability rate, and is the most common cause of cardiogenic stroke
In the past ten years, the number of people hospitalized for atrial fibrillation (AF) has increased by 23% worldwide.
For patients with atrial fibrillation, the main goal of treatment is to control symptoms and prevent heart failure and prevention of arterial thrombosis embolism, especially stroke
For patients with atrial fibrillation, the main goal of treatment is to control symptoms and prevent heart failure and prevention of arterial thrombosis embolism, especially stroke
Among them, conversion of sinus rhythm and control of ventricular rhythm are two important treatments for patients with atrial fibrillation
To better evaluate the systemic treatment of early rhythm control (the ERC; antiarrhythmic drugs or catheter ablation) compared to the usual care (the UC, allowing improved treatment of symptoms rhythm control), on failure affect atrial fibrillation patients with heart failure
The study defined heart failure as compliance with NYHA Class II-III or left ventricular ejection fraction [LVEF] <50%
At a median follow-up of 5.
Compared with patients randomized to receive UC therapy (130/402; 7.
During the follow-up period, the cumulative risk of events in the UC and ERC groups
Although the left ventricular ejection fraction improved in both groups (left ventricular ejection fraction changes after two years: ERC 5.
Although the left ventricular ejection fraction improved in both groups (left ventricular ejection fraction changes after two years: ERC 5.
Thus, it can be seen that patients with signs or symptoms of heart failure who start heart rhythm control therapy within one year after the diagnosis of atrial fibrillation will bring clinical benefits
references:
Early Rhythm Control Therapy in Patients with Atrial Fibrillation and Heart Failure.
Early Rhythm Control Therapy in Patients with Atrial Fibrillation and Heart Failure.
Leave a message here
